Physician profile
Jinyi Bae
NPI 1871154526
$2,462.54
in general payments reported to CMS, 2019-2025
13 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,261 · 2024: $971 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379 · Education: $83.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,378.90 |
| Education | $83.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $431.23 | 2023-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $340.97 | 2023-2024 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $315.21 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $302.09 | 2023-2024 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $299.38 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $260.44 | 2023-2024 | |
| Lundbeck LLC | $177.86 | 2023-2024 | Rexulti |
| Acadia Pharmaceuticals INC | $109.20 | 2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $100.47 | 2023-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $72.57 | 2023-2024 | Hetlioz, Fanapt |
| Tempus Ai, INC | $25.00 | 2024 | |
| Viiv Healthcare Company | $15.43 | 2024 | Apretude |
| Idorsia Pharmaceuticals US INC | $12.69 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinyi Bae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.